Joe Fitzgerald was named Chief Operating Officer of Boston Scientific Corp, effective January 1, 2027. As of November 6, 2026, Boston Scientific Corp has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from September 23, 2026 to October 7, 2026, naming 3 appointments and 1 departure (Form 8-K, October 7, 2026).
BOSTON SCIENTIFIC CORP announced the departure of its Executive Vice President on Sep 23. 30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Boston Scientific Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Boston Scientific Corp reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-09-23 to 2026-10-07. They name 4 people, with 3 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Boston Scientific Corp files it.
Layoffs on record: 1 filing or notice, latest 2026-07-27 (layoff filings and notices).
Also on the record for Boston Scientific Corp
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 3.1% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 5.1% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 7.47% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| August 6, 2025 | Stake report, Schedule 13G/A, by FMR LLC | 7.5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Boston Scientific Corp now and the warning signs.
Free to see. No signup.
Keep reading
More on Boston Scientific Corp and the records around it.
Boston Scientific Corp elsewhere on the record
- Layoff notices Jul 2026
- Who owns it
Companies that share a holder
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
- Vanguard Capital Management also filed stake reports on 1495 other companies: A10 Networks Inc (Oct 2026), Altisource Portfolio Solutions SA (Oct 2026), Alto Neuroscience Inc (Oct 2026)
- The Vanguard Group also filed stake reports on 2384 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch Boston Scientific Corp
Get an email when Boston Scientific Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Boston Scientific Corp?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Boston Scientific Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Boston Scientific Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-07 | In | Chief Operating Officer | 2027-01-01 | 8-K, 2026-10-07 | |
| 2026-10-07 | In | Senior Vice President, Global Finance Controller and Finance | 2027-03-01 | 8-K, 2026-10-07 | |
| 2026-10-07 | In | Chief Accounting Officer | 2027-03-01 | 8-K, 2026-10-07 | |
| 2026-09-23 | Out | Executive Vice President | 2027-01-01 | 8-K, 2026-09-23 |
Who leads Boston Scientific Corp, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Accounting Officer: Mark Bickel, appointed, effective 2027-03-01 (filed 2026-10-07).
- Senior Vice President, Global Finance Controller and Finance: Emily Woodworth, appointed, effective 2027-03-01 (filed 2026-10-07).
- Executive Vice President: Arthur C. Butcher, departure reported, effective 2027-01-01 (filed 2026-09-23). No successor is named in these filings.
- Chief Operating Officer: Joe Fitzgerald, appointed, effective 2027-01-01 (filed 2026-10-07).
New leaders reset buying decisions — get the Full Report on Boston Scientific Corp: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Operating Officer at Boston Scientific Corp, with the record behind each one.
Find candidates like Chief Operating Officer at Boston Scientific CorpEvery change, in the filing's words
Appointed: Joe Fitzgerald, Chief Operating Officer, effective 2027-01-01
Chief Operating Officer On October 7, 2026, Boston Scientific Corporation (the "Company") announced that Joe Fitzgerald, who currently serves as Executive Vice President and Group President, Cardiovascular, has been promoted to Executive Vice President and Chief Operating Officer of the Company, effective as of January 1, 2027.
Appointed: Emily Woodworth, Senior Vice President, Global Finance Controller and Finance, effective 2027-03-01
Chief Accounting Officer On October 1, 2026, the Company's Board of Directors appointed Emily Woodworth (Collins) as Senior Vice President, Global Finance Controller and Finance Transformation, effective as of March 1, 2027.
Appointed: Mark Bickel, Chief Accounting Officer, effective 2027-03-01
Also on October 1, 2026, the Company's Board of Directors appointed Mark Bickel, age 49, as Senior Vice President, Global Accounting Controller and Chief Accounting Officer, effective as of March 1, 2027.
- Mr. Fitzgerald, age 63, joined the Company in 1990, and has held a variety of management positions in the Company's Cardiovascular business.
- In his current position, which he has held since May 2022, Mr. Fitzgerald oversees development and commercialization of advanced heart therapies for health care professionals and patients globally.
- Prior to that, Mr. Fitzgerald served as Executive Vice President and President, Cardiology from January 2022 to April 2022, as Executive Vice President and President, Interventional Cardiology from July 2020 to January 2022, as Executive Vice President and President, Rhythm Management from 2014 to 2020, and as Senior Vice President and President, Cardiac Rhythm Management from 2011 to 2014, as well as various roles of increasing responsibility prior to that.
- Mr. Fitzgerald is a member of the Company's Global Council for Inclusion and is executive sponsor of the Company's Women's Network employee resource group.
- Mr. Fitzgerald received an MBA from Southern Illinois University with a concentration in marketing and finance and a BS in business from Indiana University.
- The Company has previously entered into an Indemnification Agreement with Mr. Fitzgerald on the Company's standard form for its executive officers, as previously filed with the SEC.
Departing: Arthur C. Butcher, Executive Vice President, effective 2027-01-01
On September 21, 2026, Arthur C. Butcher informed Boston Scientific Corporation (the "Company") that he has decided to retire from his role as Executive Vice President and Group President, MedSurg and Asia Pacific effective as of January 1, 2027.
- Mr. Butcher is expected to remain with the Company as a senior advisor from such time through February 26, 2027 (such date, or any earlier date, the "Retirement Date").
- As a senior advisor, Mr. Butcher will receive a base salary at his current annual base salary of $780,000, prorated through the Retirement Date.
- The Company expects to enter into a Retirement Agreement with Mr. Butcher effective as of the Retirement Date, pursuant to which Mr. Butcher will be entitled to payments and benefits that are materially consistent with those Mr. Butcher is entitled to under, and subject to the terms and conditions of, the Company's Executive Retirement Plan, 2026 Annual Bonus Plan and Long-Term Incentive Program and equity awards granted thereunder, respectively, each as previously filed with the U.S. Securities and Exchange Commission.
Tools for this story
Each opens in a new tab, filled in for Boston Scientific Corp. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.